Apolipo. B/A-1 Ratio

Understand what Apolipo. B/A-1 Ratio signals

Primary unit: ratio
LOINC codes: 55724-9, 1869-7, 1874-7, 1884-6
Commercial laboratory assays: 3

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for Apolipo. B/A-1 Ratio

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

Apolipoprotein Assessment

Laboratory: Labcorp
Test code: 216010
Specimen: Serum
Fasting: Not stated
LOINC: 55724-9
Turnaround: 1 - 2 days

Laboratory assay overview

Studies have shown that the ratio of apolipoprotein A-1:apolipoprotein B may correlate better with increased risk of coronary artery disease (CAD) than total cholesterol, and LDL:HDL ratio.

View complete laboratory reference notes

See tables. Apolipoprotein A-1 Male (mg/dL) 0 to 14 d | 62−91 15 d to 11 m | 53−175 1 to 5 y | 80−164 6 to 12 y | 107−175 >12 y | 101−178 Female (mg/dL) 0 to 14 d | 71−97 15 d to 11 m | 53−175 1 to 5 y | 80−164 6 to 80 y | 116−209 >80 y | 114−214 Apolipoprotein B1 Age | Male (mg/dL) | Female (mg/dL) 0 to 14 d | 9−67 | 9−67 15 d to 11 m | 19−123 | 19−123 1 to 5 y | 41−93 | 41−93 >5 y | 52−135 | 54−133 Apolipoprotein B:A-1 Ratio Male | Female Average risk | 0.7 | 0.6 2x average risk | 0.9 | 0.9 3x average risk | 1.0 | 1.0

Labcorp test directory, test code 216010

Apolipoprotein Evaluation

Laboratory: Quest Diagnostics
Test code: 7018
Specimen: Serum
Fasting: Not stated
LOINC: 1869-7, 1874-7, 1884-6

Laboratory assay overview

Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

Population	Range
Male	≥115 mg/dL \|
Female	≥125 mg/dL \|
Risk Category	Male \| Female
Optimal	≥115 mg/dL \| ≥125 mg/dL
High	<115 mg/dL \| <125 mg/dL
Apolipoprotein B	<90 mg/dL
Risk Category	not stated
Optimal	<90 mg/dL
Moderate	90-129 mg/dL
High	≥130 mg/dL
Male	<0.77 \|
Female	<0.63 \|
Risk Category	Male \| Female
Optimal	<0.77 \| <0.63
Moderate	0.77-0.95 \| 0.63-0.78
High	>0.95 \| >0.78

View complete laboratory reference notes

Apolipoprotein A1 Male | ≥115 mg/dL Female | ≥125 mg/dL Risk Category | Male | Female Optimal | ≥115 mg/dL | ≥125 mg/dL High | <115 mg/dL | <125 mg/dL Cardiovascular event risk category cut points (optimal, high) are based on the AMORIS study, Walldius G et al. J Intern Med. 2004;255:188-205. Apolipoprotein B | <90 mg/dL Risk Category Optimal | <90 mg/dL Moderate | 90-129 mg/dL High | ≥130 mg/dL A desirable treatment target may be <80 mg/dL or lower depending on the risk category of the patient including patients on lipid lowering therapies, patients with ASCVD, diabetes with >1 risk factors, Stage 3 or greater CKD with albuminuria, or heterozygous familial hypercholesterolemia. ApoB relative risk category cut points are based on AACE/ACE and ACC/AHA recommendations (Grundy SM, et al. 2019. doi:10.1016/j.jacc.2018.11.002; Handelsman Y, et al. 2020. doi:10.4158/CS-2020-0490). Apolipoprotein B/A1 Ratio Male | <0.77 Female | <0.63 Risk Category | Male | Female Optimal | <0.77 | <0.63 Moderate | 0.77-0.95 | 0.63-0.78 High | >0.95 | >0.78 Cardiovascular event risk category cut points (optimal, moderate, high) are based on the AMORIS study, Walldius G et al. J Intern Med. 2004;255:188-205.

Quest Diagnostics test directory, test code 7018

Cardio IQ® Apolipoprotein Evaluation

Laboratory: Quest Diagnostics
Test code: 91727
Specimen: Serum
Fasting: Not stated
LOINC: 1869-7, 1874-7, 1884-6

Laboratory assay overview

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

Population	Range
Male	≥115 mg/dL \|
Female	≥125 mg/dL \|
Risk Category	Male \| Female
Optimal	≥115 mg/dL \| ≥125 mg/dL
High	<115 mg/dL \| <125 mg/dL
Apolipoprotein B	<90 mg/dL
Risk Category	not stated
Optimal	<90 mg/dL
Moderate	90-129 mg/dL
High	≥130 mg/dL
Male	<0.77 \|
Female	<0.63 \|
Risk Category	Male \| Female
Optimal	<0.77 \| <0.63
Moderate	0.77-0.95 \| 0.63-0.78
High	>0.95 \| >0.78

View complete laboratory reference notes

Apolipoprotein A1 Male | ≥115 mg/dL Female | ≥125 mg/dL Risk Category | Male | Female Optimal | ≥115 mg/dL | ≥125 mg/dL High | <115 mg/dL | <125 mg/dL Cardiovascular event risk category cut points (optimal, high) are based on the AMORIS study, Walldius G et al. J Intern Med. 2004;255:188-205. Apolipoprotein B | <90 mg/dL Risk Category Optimal | <90 mg/dL Moderate | 90-129 mg/dL High | ≥130 mg/dL ⁠⁠⁠⁠⁠⁠⁠A desirable treatment target may be <80 mg/dL or lower depending on the risk category of the patient including patients on lipid lowering therapies, patients with ASCVD, diabetes with >1 risk factors, Stage 3 or greater CKD with albuminuria, or heterozygous familial hypercholesterolemia. ApoB relative risk category cut points are based on AACE/ACE and ACC/AHA recommendations (Grundy SM, et al. 2019. doi:10.1016/j.jacc.2018.11.002; Handelsman Y, et al. 2020. doi:10.4158/CS-2020-0490). Apolipoprotein B/A1 Ratio Male | <0.77 Female | <0.63 Risk Category | Male | Female Optimal | <0.77 | <0.63 Moderate | 0.77-0.95 | 0.63-0.78 High | >0.95 | >0.78 Cardiovascular event risk category cut points (optimal, moderate, high) are based on the AMORIS study, Walldius G et al. J Intern Med. 2004;255:188-205.

Quest Diagnostics test directory, test code 91727

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.